Clinical trials in Tampere – page 2

273 clinical trials in Tampere, Finland across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FinlandKliinisetTutkimukset.fi

Tampere at a glance

273

clinical trials

Research sites3

Quick filters

273 trials in Tampere

Open in trial search

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
Sponsor:Dr. Falk Pharma GmbH

Contact Research Centre

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Favezelimab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo

Finland

Participants:65+ years · Healthy volunteers
Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Gastrointestinal stromal tumour

Recruiting

InvestigationalNo placebo

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Imatinib Mesilate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Phase 1/2 Study Evaluating Safety and Activity of GSK5926371 in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

InvestigationalNo placebo

Finland

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

Finland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational

Finland

Participants:0–17 years
Substances:Bi 1015550
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Investigational

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:LUNSEKIMIG
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Genmab A/S

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Finland

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Incyte Corp.

Contact Research Centre

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Tampere

What the registry says about research in the country

01 Infectious Disease Prevention

Extensive research focusing on vaccine development against multiple viral infections, including influenza, RSV, and meningococcal disease. Clinical trials are evaluating novel immunization strategies for different age groups.

Influenza vaccine trials for adults 60+
RSV prevention in infants and elderly
Meningococcal vaccines for children

Multiple studies are investigating immune responses and long-term protection against respiratory infections.

02 Oncology Research

Innovative trials exploring new treatments for various cancers, with emphasis on advanced solid tumors and blood cancers. Studies combine novel therapeutic approaches with existing treatments.

Breast cancer therapies
Leukemia treatments
Prostate cancer interventions

Focus on developing targeted therapies and improving treatment outcomes for cancer patients.

03 Diagnostic Medicine

Research evaluating advanced diagnostic techniques, particularly in emergency medicine and acute conditions. Studies compare different imaging methods and their effectiveness.

CT scanning protocols
Emergency diagnostics
Treatment response monitoring

Emphasis on improving diagnostic accuracy while considering patient safety.

Back to Finland All countries

Clinical trials in Tampere – page 2

273 trials in Tampere

Coeliac disease

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Neoplasm malignant

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Influenza+1

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Gastrointestinal stromal tumour

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

Non-Hodgkin's lymphoma

Phase 1/2 Study Evaluating Safety and Activity of GSK5926371 in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Osteosarcoma

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Interstitial lung disease

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Chronic obstructive pulmonary disease

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Ovarian cancer recurrent

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Pancreatic carcinoma metastatic

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Non-small cell lung cancer+1

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Neuroendocrine carcinoma

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Filter the trials

Other cities in Finland

Clinical research in Tampere

Prefer not to search? Our Concierge searches the trials for you.

Clinical trials in Tampere – page 2

273 trials in Tampere

Influenza+1

Non-small cell lung cancer+1

Other cities in Finland

Related

Clinical research in Tampere

Prefer not to search? Our Concierge searches the trials for you.